M&A Deal Summary

Green Cross Acquires BioCentriq

On May 17, 2022, Green Cross acquired life science company BioCentriq from NJII for 73M USD

Acquisition Highlights
  • This is Green Cross’ 1st transaction in the Life Science sector.
  • This is Green Cross’ largest (disclosed) transaction.
  • This is Green Cross’ 1st transaction in the United States.
  • This is Green Cross’ 1st transaction in New Jersey.

M&A Deal Summary

Date 2022-05-17
Target BioCentriq
Sector Life Science
Buyer(s) Green Cross
Sellers(s) NJII
Deal Type Divestiture
Deal Value 73M USD

Target

BioCentriq

Newark, New Jersey, United States
BioCentriq is a US-based contract development and manufacturing organization (CDMO) that designs and develops scalable cell and gene technologies. BioCentriq was founded in 2019 and is based in Newark, New Jersey.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Green Cross

Yongin-Si, South Korea

Category Company
Founded 1967
Sector Life Science
Employees150
Revenue 2.06T KRW (2023)
DESCRIPTION

Green Cross is a holding company, which operates pharmaceuticals, biotechnology, distribution system, life insurance, and healthcare providers' total healthcare solutions that address the evolving needs of human health. Green Cross was founded in 1967 and is based in Yongin, South Korea.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

NJII

Newark, New Jersey, United States

Category Company
Founded 2014
Sector Business Services
DESCRIPTION

NJII helps turn ideas into workable solutions across four divisions: healthcare, entrepreneurship, defense, homeland security, and professional and corporate education. NJII was founded in 2014 and is headquartered in Newark, New Jersey.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1